(Reuters) -AbbVie said on Friday that the U.S. Food and Drug Administration approved its drug for complicated intra-abdominal ...

Pfizer and Merck, ostensibly beleaguered drugmakers, have seen their shares battered despite reporting strong earnings.

Drugmaker Pfizer posted a better-than-expected fourth-quarter profit on Thursday, helped by cost cuts it began last year as ...

Health experts are seeing signs of a much smaller wave of U.S. COVID-19 cases this winter than in previous years, which could ...

Last year marked the first time in Pfizer’s 175-year history that the drugmaker shelled out the requisite millions for ...

Pfizer's Q4 2024 earnings beat expectations, but concerns over 2025 guidance and patent expirations led to stock decline. See ...

Pfizer CEO Albert Bourla said there are "opportunities that probably outweigh the risks" of the Trump administration's ...

In mid-2024, the commercial president of Pfizer’s oncology unit Suneet Varma announced his retirement after 15 years with the ...

The pharmaceutical giant named Jeffrey Legos the head of a division it is counting on to overcome investor pressure and grow ...

Pfizer has ended development of a B7-H4-directed antibody-drug conjugate (ADC), triggering a $1 billion impairment charge. | ...

Unexpected demand for Pfizer Inc.’s Covid vaccine helped the company beat quarterly expectations. Then Robert F. Kennedy Jr., ...

Pfizer ( PFE) reported fourth quarter and full-year 2024 earnings results Tuesday, narrowly beating Wall Street expectations ...